Save 64% on Inrebic from Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine.
Manufacturer for Inrebic in Europe:
Celgene Distribution B.V.
Orteliuslaan 1000
3528 BD Utrecht
Netherlands
Information about Inrebic (Fedratinib)
Inrebic is an oral medication classified as a kinase inhibitor. It specifically targets the Janus kinase (JAK) pathways, which are involved in the signaling processes that affect blood cell production and inflammation. Inrebic is primarily used in the treatment of myelofibrosis, a type of bone marrow cancer that disrupts the body’s normal production of blood cells.
Product Highlights
- Treatment of myelofibrosis, including patients who have previously been treated with other therapies
- Can be used in patients with anemia associated with myelofibrosis
Key Ingredient
Key Benefits
- Reduces spleen size and alleviates symptoms associated with myelofibrosis
- May improve quality of life by addressing symptoms such as fatigue, night sweats, and weight loss
- Provides a treatment option for patients who have not responded adequately to other therapies
Direction of Use:
- Take Inrebic exactly as prescribed by a healthcare provider, typically once daily.
- Can be taken regardless of food intake.
- Dosage may be adjusted based on individual response and tolerance.
Safety Concerns
- Common side effects include nausea, diarrhea, fatigue, and elevated liver enzymes.
- Serious risks may include thrombocytopenia (low platelet count), liver toxicity, and gastrointestinal issues.
- Regular monitoring of blood counts and liver function is advised throughout the treatment.
Avoid Inrebic (Fedratinib) If
- You have a known hypersensitivity to fedratinib or any component of the formulation.
- You have active liver disease or significant liver dysfunction.
- You have a history of severe thrombocytopenia or bleeding disorders.
- You are pregnant or breastfeeding, as it could pose risks to the fetus or nursing infant.
